🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

212 results for “Bristol-Myers” Clear

  1. riliprubart, -, riliprubart placebo solution for injection in prefilled pen, placebo matching IVIg, riliprubart, riliprubart placebo solution for injection in vial, -

    Sanofi Pharma Bristol-Myers Squibb

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

  2. same excipients except no hypromellose, PREDNISONE , SAR445761 - belumosudil, PREDNISOLONE

    Sanofi Pharma Bristol-Myers Squibb

    chronic graft versus host disease

    phase 3 small molecule active

    1 trial

  3. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi Pharma Bristol-Myers Squibb

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  4. A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  5. A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 2 other active

    1 trial

  6. A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

    Sanofi Pharma Bristol-Myers Squibb

    Hidradenitis suppurativa

    phase 2 other active

    1 trial

  7. A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouth

    Sanofi Pharma Bristol-Myers Squibb

    Healthy volunteers

    phase 2 other active

    1 trial

  8. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi Pharma Bristol-Myers Squibb

    Hidradenitis

    phase 2 small molecule active

    1 trial

  9. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi Pharma Bristol-Myers Squibb

    Coeliac disease

    phase 2 small molecule active

    1 trial

  10. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi Pharma Bristol-Myers Squibb

    Alopecia areata

    phase 2 small molecule active

    1 trial

  11. Amlitelimab, Placebo

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    phase 2 small molecule active

    1 trial

  12. An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    phase 2 other active

    1 trial

  13. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb / Pfizer EEIG

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  14. BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB

    Bristol-Myers Squibb / Pfizer EEIG

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  15. BMS-986470, BMS-986470, N/A, BMS-986470

    Bristol-Myers Squibb / Pfizer EEIG

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  16. BMS-986517

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  17. BMS-986523, BMS-986523

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  18. BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  20. Balinatunfib, Not the same excipients as test

    Sanofi Pharma Bristol-Myers Squibb

    Crohn's disease, Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  21. CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED

    Bristol-Myers Squibb / Pfizer EEIG

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  22. CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., PACLITAXEL, anti-NKG2A mAb, CARBOPLATIN, PEMETREXED DISODIUM

    Bristol-Myers Squibb / Pfizer EEIG

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb / Pfizer EEIG

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  24. DASATINIB, Dasatinib, dasatinib, dasatinib

    Bristol-Myers Squibb / Pfizer EEIG

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources